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Objectives. This study attempted to determine whether neutro- 
phil sequestration i  reperfused myocardium can be inhibited and 
infarct size reduced by treatment with a chimeric, monoclonal 
IgG4 antibody (CLB54) directed against CD18 in a primate model 
of acute myocardial ischemia and reperfusion. 
Background. Reperfusion i jury, in part mediated by neutro- 
phils, may limit the potential benefit of reestablishing infarct- 
related artery patency in patients with acute myocardial infarc- 
tion. 
Methods. Nineteen closed-chest baboons (10 control, 9 treated 
with CLB54) had the left anterior descending coronary artery 
occluded for 90 rain, followed by 4 h of reflow. CLB54 (mean 
[-+SD] 11 +- 2 mg/kg body weight) or saline solution was 
administered intravenously 20 rain before reflow. Coronary flow 
was determined using radiolabeled microspheres, infarct size by 
triphenyltetrazolium chloride staining, global and regional yen- 
tricular function by contrast ventriculography and neutrophil 
accumulation by a myeloperoxidase say. 
Results. Risk region size was the same in both groups. CLB54 
treatment reduced infarct size expressed as a percent of the risk 
region from 41 -+ 20% in the saline-treated group to 19 + 17% in 
the CLB54-treated group (p < 0.02). This was associated with 
diminished myeloperoxidase activity and greater postreperfusion 
coronary flow in the risk region in CLB54-treated than in control 
baboons. Ejection fraction declined to the same extent in both 
groups, whereas anterior wall regional cord shortening was better 
preserved in CLB54-treated baboons. 
Conclusions. Inhibition of neutrophil sequestration with 
CLB54 administered before reperfusion reduces infarct size, 
preserves ischemic zone microvascular perfusion and minimizes 
the decline of regional wall motion. 
(JAm Coil Cardiol 1995;25:781-8) 
In acute myocardial infarction, establishing patency of the 
occluded coronary artery with thrombolytic therapy has bene- 
ficial effects on left ventricular function and mortality (1-3). 
Nevertheless, tudies in cardiac and noncardiac animal models 
of ischemia nd reperfusion (4-9) suggest that vascular and 
parenchymal tissue injury can occur as a result of reperfusion 
itself, thus reducing the potential benefit of restoring flow. For 
this reason, strategies designed to minimize reperfusion i jury 
have been sought. 
A number of factors and cell types are thought to contribute 
to reperfusion i jury (10-13). Although these mechanisms are 
part of the normal process of "inflammation and repair," in 
reperfusion i jury these pathophysiologic processes are con- 
sidered to have "gone awry," extending necrosis more than 
promoting repair. The polymorphonuclear leukocyte has been 
the focus of particularly intense study. Potentially deleterious 
effects of neutrophils inreperfused tissue include direct paren- 
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chymal tissue injury through generation of free radicals (10) 
and release of lysosomal enzymes and injury secondary to 
effects on the microcirculation (11-16). 
Neutrophil adhesion to endothelial cells is mediated by a 
number of specific adhesion molecules, including L-setectins 
and the CDll/CD18 family of beta-integrins and their endo- 
thelial cell counterreceptors (17). Because the beta-integrin 
family of adhesion molecules appears to mediate firm attach- 
ment of neutrophils to endothelial cells through the endothe- 
lial cell counterreceptor intercellular adhesion molecule 
(ICAM)-I, and because such attachment is a necessary first 
step to subsequent diapedesis, monoclonal ntibodies directed 
against CD11/CD 18 have therapeutic potential in reducing the 
neutrophil-mediated component of reperfusion injury. The 
present study was undertaken to test the anti-CD18 antibody 
CLB54 as a therapy to reduce infarct size in a primate model 
of acute ischemia followed by reperfusion. 
In preliminary studies, the appropriate dose of CLB54 was 
determined by a combination of in vitro and in vivo dose- 
response testing. After determining the appropriate dose of 
CLB54, an infarct size study was performed that showed that 
administration f CLB54 just before reflow reduces infarct size 
by 50% by a mechanism associated with reduced neutrophil 
sequestration in previously ischemic reperfused myocardium. 
@1995 by the American College of Cardiology 0735-1097/95/$9.50 
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CLB54 treatment was also associated with preservation of 
microvascular perfusion and regional myocardial function in 
the ischemic zone. 
Methods 
The chimeric CLB54 monoclonal antibody used in this 
study is a human/mouse g netic reconstruction f a murine 
monoclonal IgG4 molecule that binds selectively to the neu- 
trophil CD18 receptor. It was supplied as a sterile, nonpyro- 
genie solution of 5 mg of monoclonal IgG4 per milliliter of 
buffer solution containing 0.15 tool/liter of sodium chloride, 
0.01 tool/liter of sodium phosphate and 0.01% of polysorbate 
80 at pH 6.5 (Centocor, Inc.). 
In vitro methods. Neutrophil isolation. Five milliliters of 
heparinized blood was diluted 10-fold with ice-cold buffer 
(0.155 mol/liter ammonium chloride, 10 retool/liter potassium 
bicarbonate, 0.1 retool/liter ethylenediaminetetraacetic acid 
[EDTA], pH 7.4) and incubated 10 rain on ice to lyse red cells. 
Cells were pelleted 5 rain at 1,500 rpm, resuspended in 10 ml 
of cold lysis buffer, centrifuged and resuspended in 0.5 ml of 
Hank's balanced salt solution (HBSS)/5 ml of starting blood 
volume. 
Neutrophil adhesion assay. Human umbilical vein endothe- 
lial cells (HUVECs) (Cell Systems) were obtained at passage 1
and cultured and used at passage 4. Cells were grown to 
confluence on gelatin-coated 96-well plates and stimulated 
with 50 tzg/ml of tissue necrosis factor-alpha (Genzyme) for 
24 h. 
Medium was removed from the HUVECs and replaced 
with HBSS containing 5 mg/ml of human serum albumin; 50 tzl 
of a 4.0 × 106 cells/ml suspension of neutrophils was added to 
the wells for 15 rain at 37°C. Unbound cells were removed by 
two 200-/A HBSS washes. Cells were solubilized with 200 ~1 of 
0.5% hexadecyltrimethylammonium bro ide (HTAB) in 
50 retool/liter potassium phosphate at pH 6.0 (HTAB buffer). 
Bound neutrophils were quantified by myeloperoxidase assay. 
Myeloperoxidase assay for neutrophil adhesion assay. The 
following solutions were sequentially pipetted into 96-well 
flat-bottomed polystyrene microtitration plates (volumes are 
per well): 15-~1 sample; 55 /.tl of 80 retool/liter potassium 
phosphate buffer, pH 5.4; 20 /~1 of 0.3 retool/liter hydrogen 
peroxide in 80 mmol/liter potassium phosphate buffer, pH 5.4; 
10 /xl of 16 retool/liter 3,3',5,5'-tetramethylbenzidine (Sigma 
Corp.) N,N-dimethylformamide. Plates were developed for 
10 rain at room temperature and then stopped with 100 tzl/well 
of 1 tool/liter phosphoric acid and optical density read at 
450 nm. 
Iodine-125-1abeled CLB54 binding to neutrophils. Neutro- 
phils were resuspended in HBSS to 4.0 × 106 cells/ml and 
aliquoted 50 /A/well into 96-well polyvinyl chloride plates. 
Neutrophils were incubated for 60 rain at 37°C with iodine- 
125-labeled CLB54 (specific activity 2 tLCi//~g) added to a final 
concentration f 40/~g/ml. Cells were washed with 200/xl of 
HBSS and pelleted three times. The cell pellet was finally 
solubilized and counted in a gamma counter. 
Quantification of free antibody levels. Ninety-six-well 
enzyme-linked immunosorbent assay (ELISA) plates were 
coated overnight with 10 ~tg/ml of rabbit anti-CLB54 IgG in 
coating buffer (1.6 g/liter of anhydrous odium carbonate, 
2.93 g/liter of sodium bicarbonate) and then washed three 
times with 250 /zl/well of ELISA wash buffer (9 g/liter of 
sodium chloride, 0.2 g/liter of Tween-20). Plates were blocked 
1 h at 37°C with 200-/~l/well human anti-mouse antibody 
(HAMA) diluent (45% goat serum, 35% fetal bovine serum, 
20% phosphate-buffered serum). Samples were added 50 
txl/well, initially diluted 1:10 in HAMA diluent and further 
diluted 1:2 in HAMA diluent with the final dilution of 1:640, 
for 1 h at room temperature. A standard curve of chimeric 
antibody (50 to 0.006 ~g/ml) in baboon plasma was also tested. 
Plates were washed three times with 250 ~1 of ELISA wash 
buffer. Then, 50 ~1 of alkaline phosphatase conjugated antihuman 
H+L antibody (1/~g/ml) was added to each well and incubated 
for 1 h at room temperature. After three washes with 250 ill of 
ELISA wash buffer, 100/zl of alkaline phosphatase ubstrate was 
added to each well and allowed to incubate 15 rain at room 
temperature. The reaction was stopped with 50 pJ of 3 N sodium 
hydroxide, and the optical density at 405 nm was read. The optical 
densities of samples that fell on the linear portion of the standard 
curve were used to calculate the concentration f free antibody in 
the plasma. 
In vivo methods. Reverse Arthus reaction. Ten baboons 
were tranquilized with ketamine (15 mg/kg body weight intra- 
muscularly), and an extremity vein was cannulated with a 
standard 21-gauge butterfly needle; 15 mg/kg of bovine serum 
albumin (Sigma Corp.) was administered intravenously. The 
skin on one or both forearms was shaved, 0.1 to 0.2 ml of saline 
solution or rabbit anti-bovine serum albumin (Sigma Corp.), 
minimum 2mg of anti-bovine serum albumin/ml) was injected 
intradermally using a 25-gauge tuberculin syringe, and the 
injection sites were marked and labeled. Sites were examined 
grossly, and full-thickness kin biopsies were performed at 
24 h. Six control baboons received no CLB54; one baboon was 
treated with 1 mg/kg, one with 3 mg/kg, one with 9 mg/kg and 
one with 11 mg/kg of CLB54 administered intravenously just 
after bovine serum albumin administration. Blood samples for 
CLB54 concentration were obtained before and 5 rain and 1, 3, 
5 and 24 h after CLB54 administration. Development of 
edema, induration and hemorrhage atthe site of anti-bovine 
serum albumin injection was monitored over 24 h, and the 
reaction was graded semiquantitatively on a 0 (no reaction) to 
4+ (edema, hemorrhage, induration) scale. At 24 h full- 
thickness biopsy samples of the lesions were obtained and were 
stained with hematoxylin-eosin. Neutrophil infiltration was 
graded on a 0 (normal biopsy) to 4+ (sheets of neutrophils, 
hemorrhage and edema) semiquantitative scale. 
Infarct model. This infarct model was used in both a 
preliminary dose-finding study and in the final infarct-size 
study (see Results). 
Baboons (20 to 30 kg) of either gender were tranquilized 
with ketamine (15 mg/kg) and were intubated and ventilated 
with supplemental oxygen and 1% to 2% halothane inhalation 
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anesthetic. Halothane concentration was adjusted to keep the 
baboons anesthetized throughout the experiment while main- 
taining stable arterial blood pressure. 
Both femoral arteries and the right femoral vein were 
isolated by direct exposure and cannulated with 7F sheaths 
(Cordis, Inc.). The arterial sheaths were used to introduce 
various required catheters, and their sidearms were used for 
reference sample withdrawal for microsphere measurements 
of coronary blood flow (see later). The venous heath was used 
for administration f fluid and drugs as required. After femoral 
vessel cannulation, 10,000 IU of heparin was administered 
intravenously. For coronary angiography and placement of the 
angioplasty balloon (see later), a 7F angioplasty guiding cath- 
eter (standard AL-I or custom-made JL-2.5 [Cordis, Inc.]) was 
advanced over a 0.035-in. (0.89 mm) guide wire into the 
ascending aorta through a femoral artery sheath and the left 
coronary ostium engaged. For left ventriculography, aortic 
pressure measurement and microsphere administration, a 6F 
pigtail catheter (Cordis, Inc.) was advanced over a 0.035-in. 
guide wire into the ascending aorta through the other femoral 
artery sheath. The pigtail catheter could be advanced retro- 
gradely into the left ventricle or withdrawn into the ascending 
aorta, as needed. 
End-expiratory carbon dioxide, lead I or II of the electro- 
cardiogram (ECG) and aortic pressure were monitored 
throughout the procedure. 
Left ventriculography. Left ventriculography was performed 
in the 45 o right anterior oblique projection. The pigtail catheter 
was advanced into the left ventricular cavity, and 6 to 8 ml/s of 
nonionic ontrast was injected for a total of 24 to 32 ml through 
the pigtail catheter using an automatic, calibrated power 
injector (MedRad, Inc.). The ventriculogram was recorded 
cineangiographically at 30 frames/s, and a calibration grid was 
filmed at heart level immediately afterward. 
For analysis, asingle end-diastolic and end-systolic frame of 
the baseline and end-study contrast ventriculogram was digi- 
tized, and the ventricular contours were traced using a mouse 
cursor and a commercial digitizing package (Image Comm, 
Inc.). The end-diastolic and end-systolic left ventricular vol- 
umes were determined using the filmed grid for calibration 
(single-plane modification of the Sandier-Dodge area-length 
method [18]), and stroke volume and ejection fraction (stroke 
volume expressed as a percent of end-diastolic volume) were 
calculated. Regional chord shortening along 100 chords from 
the base of the anterior wall to the base of the inferior wall was 
determined, as previously described (19). The right anterior 
oblique left ventricular contour was divided into five segments 
(anterobasal, midanterior, apical, midinferior and inferobasal) 
of 20 chords each, and the median chord shortening was 
determined for each region. Regional function was defined as 
the median chord shortening for each of these regions. 
Microsphere blood flow. For microsphere blood flow mea- 
surements, the pigtail catheter was placed in the left ventricle. 
Reference sample withdrawal from the sidearm of a femoral 
artery sheath was begun at 2.16 ml/min using a calibrated 
withdrawal pump (Harvard, Inc.) just before microsphere 
administration. Then, 1 to 2 million 15-/xm microspheres 
labeled with Gd-152, Sn-ll3, Sc-46 or Nb-95 were adminis- 
tered into the left ventricle through the pigtail catheter. The 
catheter was then withdrawn i to the aorta, and aortic pressure 
and the ECG were recorded. Reference sample withdrawal 
was terminated no sooner than 2 min after microsphere 
injection. 
Regional coronary blood flow in myocardial samples (see 
later) was determined by counting each myocardial nd refer- 
ence sample for 10 min in a gamma counter and correcting 
counts for background and overlap. Coronary blood flow 
(CBF) in a myocardial sample was then given as follows: CBF 
(ml/min/g) = cpm/g (tissue)/cpm (reference) x 2.16 ml/min, 
where cpm/g (tissue) = corrected counts per minute per gram 
tissue, and cmp (reference) = corrected counts per minute in 
the reference sample. 
Protocol. Aortic or left ventricular pressure, heart rate and 
the ECG were monitored continuously throughout the proce- 
dure and recorded periodically. The pigtail catheter was ad- 
vanced into the left ventricle, and a right anterior oblique 
ventriculogram obtained. Cineangiography of the left coronary 
circulation was performed inthe right and left anterior oblique 
projections, and the approximate size of the proximal eft 
anterior descending coronary artery was estimated, using the 
diameter of the 7F angioplasty guiding catheter for calibration. 
The appropriate-sized angioplasty balloon (Slider ST, Mans- 
field, Inc.) was selected and was advanced using fluoroscopic 
visualization over a 0.014-in. (0.36 mm) guide wire into the 
proximal left anterior descending artery. The balloon was then 
inflated to 3 arm of pressure (45 psi). Coronary occlusion was 
confirmed with contrast cineangiography initially and periodi- 
cally throughout the protocol. 
Twenty minutes before occlusion release, either saline 
solution (control baboons) or CLB54 (treated baboons) was 
administered intravenously as a bolus. 
Before occlusion release, a final cineangiogram was ob- 
tained, microsphere coronary flow was measured and aortic 
and left ventricular pressure and the ECG were recorded. The 
angioplasty balloon was then deflated and removed with the 
guide wire from the coronary artery. Serious ventricular ar- 
rhythmias (sustained ventricular tachycardia or ventricular 
fibrillation requiring defibrillation) were treated with a single 
dose of lidocaine, 30 mg intravenously. This was repeated only 
if serious arrhythmias returned. No baboon was treated with 
continuous infusion of lidocaine. 
Ten minutes and 4 h after occlusion release, cineangio- 
grams, microsphere coronary flow, systemic pressures and the 
ECG were recorded. Just before sacrifice, the right anterior 
oblique left ventriculography was repeated. Animals were 
killed by intraventricular administration f hyperkalemic solu- 
tion through the pigtail catheter. 
Estimation of risk region and infarct size. After sacrifice, the 
heart was removed, the right ventricle and both atria were 
trimmed, and the heart was cut transversely into five to six 
1-cm thick rings from base to apex, which were weighed and 
placed for 15 rain in 1% triphenyltetrazolium chloride to 
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distinguish infarcted from noninfarcted myocardium. The mass 
of infarcted and noninfarcted tissue was estimated by digital 
planimetry of color 35-mm slides of the stained myocardial 
rings. The ratio of planimetered infarct area to planimetered 
total area for each ring was multiplied by ring weight to 
determine infarct mass for each ring; infarct masses for all 
rings were then summed to determine total infarct mass. 
Infarct mass as a percent of the left ventricular mass (weighed) 
was calculated from these measurements. 
Risk and nonrisk regions were defined by microsphere 
blood flow. Hearts were sectioned into 70 to 100 samples, and 
blood flow at the end of coronary occlusion for each sample 
was determined. A sample was defined as being from the area 
at risk if flow was <50% of flow in the nonrisk region. Risk 
region mass was calculated by summing the weights of all 
risk region samples o defined. Infarct mass as a percent of risk 
mass and risk region mass as a percent of the left ventricular 
mass were calculated, using infarct mass determined by digital 
planimetry and total left ventricular mass by direct weighing. 
Regions of no or low reflow were defined as samples taken in 
the risk region that at 4 h of reflow had <50% of simultaneously 
determined nonischemic zone coronary flow. 
Myeloperoxidase assay. Myeloperoxidase activity was mea- 
sured as previously described (20). After triphenyltetrazolium 
chloride staining, 50- to 150-mg samples were obtained from 
the endocardium and epicardium of the central ischemic and 
the nonischemic regions and were weighed and frozen at 
-70°C. Samples were pulverized under liquid nitrogen, ho- 
mogenized and sonicated and then underwent three rounds of 
freeze-thaw to release myeloperoxidase. Myeloperoxidase ac- 
tivity was measured by adding O-dianisidine hydrochloride and 
hydrogen peroxide and then observing the change in light 
absorbance ata wavelength of460 nm for 2 min. Results were 
expressed as units of myeloperoxidase per 100 mg wet weight 
of the samples. 
Statistics. All data are reported as mean value 2 SD. 
Comparisons of two means were performed using an unpaired 
Student  test if the data were normal and a Mann-Whitney 
nonparametric test for significance for data that were not 
normal. When more than two means were compared, analysis 
of variance was performed first, and a t test corrected for 
multiple comparisons was performed to detect significant 
differences between any two mean values. M1 statistics were 
performed using Systat version 5.0 (Systat, Inc.). 
Results 
Preliminary studies. In vitro antibody characterization. 
There was a 100-fold difference between the concentration f 
CLB54 required for half-maximal occupancy of CD18 receptor 
sites on neutrophils and the concentration required in whole 
blood for half-maximal inhibition of neutrophil adhesion. The 
concentration f CLB54 required for half-maximal occupancy 
of CD18 receptors in isolated human neutrophils was 0.2 
txg/ml. Half-maximal inhibition of isolated human neutrophil 
adhesion to tumor necrosis factor-alpha-stimulated HUVECs 
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Figure 1. Serum blood levels after four different intravenous doses of 
CLB54 in four different baboons. 
was 10 times higher at 2 ~g/ml. Treatment of whole human 
blood with chimeric anti-CD18 required 20 ixg/ml of antibody 
for half-maximal inhibition of neutrophil binding to tumor 
necrosis factor-alpha-stimulated HUVECs. 
In vivo antibody characterization. In vivo characteristics of 
CLB54 were examined in several dose-response tudies. 
Plasma levels of free antibody achieved at various doses of 
CLB54 (from four baboons that received CLB54 in the reverse 
passive Arthus reaction) are shown in Figure 1. At the higher 
doses, CLB54 levels increased rapidly and were sustained for 
24 h after administration. Neutrophil count increased signifi- 
cantly after administration f CLB54 at the higher dosage. 
Reverse passive Arthus reaction. The reverse passive Arthus 
reaction was associated with moderate gross and histologic 
evidence of inflammation in non-CLB54-treated animals 
(2.3 _+ 1.0 and 2.5 -+ 1.5 reaction grade, respectively, on a scale 
of 0 to 4). Neither 1- nor 3-mg/kg doses of CLB54 reduced 
either gross or histologic evidence of inflammation. However, 
in both baboons treated with an average of 10 mg/kg of CLB54 
(9 and 11 mg/kg), the reaction was completely abolished 
grossly (0 reaction grade in both) and minimized histologically 
(1 reaction grade in both). 
Preliminary infarct studies. In preliminary studies, an aver- 
age dose of 5 - 4 mg/kg in six baboons failed to reduce infarct 
size, expressed as a percent of risk region, compared with 
results in the control animals (control group 41 _+ 20% vs. 
CLB54 treatment 44 _+ 22%) despite equal risk region sizes 
(-35% of the left ventricle). Early postreperfusion ischemic 
zone coronary blood flow expressed as a percent of nonisch- 
emic zone flow was the same in the control and CLB54-treated 
groups (113 _+ 50% vs. 120 _+ 21%). Neutrophil levels were 
measured inonly three of six CLB54-treated baboons but were 
modestly reduced compared with control animals (1.6 _+ 1.1 vs. 
1.0 -+ 0.3 U/100 mg left ventricle for control vs. CLB54-treated 
animals, respectively). On the basis of these preliminary data 
and the reverse passive Arthus reaction data, subsequent 
studies and analyses were performed using CLB54 doses 
->10 mg/kg. (Doses >10 mg/kg were used in two baboons to 
determine whether further infarct size reduction could be 
obtained at higher doses.) 
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Ex vivo antibody characterization. The effect of CLB54 
(10 mg/kg, plasma concentrations of -400 to 500/xg/ml) on 
binding of neutrophils to HUVECs from two baboons was 
studied ex vivo. Baboon blood samples were collected before 
and 5 (two animals) and 30 rain (one animal) after antibody 
administration, and neutrophils were isolated. Neutrophil 
binding to both unstimulated and tumor necrosis factor-alpha- 
stimulated HUVECs was reduced by 50 _+ 6% at 5 min and by 
63% 30 min after CLB54 administration to levels comparable 
to control neutrophil binding to unstimulated HUVECs. Fur- 
thermore, binding of iodine-125-1abeled anti-CD18 to the 
neutrophils isolated from whole-blood samples from CLB54- 
treated baboons revealed that there were no residual CD18 
sites available for further antibody binding, suggesting 100% 
occupancy of CD18 by CLB54. 
Infarct model. As a result of in vivo and ex vivo antibody 
characterization, subsequent studies and analysis were per- 
formed using CLB54 at doses ->10 mg/kg. (Doses >10 mg/kg 
were used in two baboons to determine whether further infarct 
size reduction could be obtained at higher doses.) 
A total of 22 baboons (11 control and 11 CLB54 treated) 
were studied. Two animals died at onset of coronary occlusion 
(one control, one CLB54 treated) and were not analyzed 
further. In one CLB54-treated baboon, the occluding balloon 
inflation pressure decreased uring the occlusion period. Be- 
cause it was unknown whether coronary flow occurred uring 
the period of lowered pressure, data from this animal (which 
had an infarct smaller than the mean size for the CLB54- 
treated group) were not used. Ten control and nine CLB54- 
treated baboons completed the protocol. The CLB54-treated 
animals received an average dose of 11 _+ 2 mg/kg (range 10 to 
15). 
Hemodynamic variables. Before coronary occlusion in con- 
trol and CLB54-treated baboons, aortic systolic blood pres- 
sure was 101 _ 18 and 103 _+ 15 mm Hg, aortic diastolic 
pressure 69 _+ 10 and 73 _+ 13 mm Hg, and heart rate 99 _+ 12 
and 109 _+ 15 beats/min, respectively. Aortic blood pressures 
and heart rate did not change significantly during the course of 
the protocol and were not different in control and CLB54- 
treated baboons at any time. 
Infarct size. Figure 2 summarizes risk region and infarct 
sizes in control and CLB54-treated baboons. Risk regions were 
not significantly different in the two groups (37 + 9% vs. 41 __ 
11%, control vs. CLB54-treated animals, respectively). CLB54 
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Figure 2. Risk region (RISK) and infarct (INF) size as a percent of the 
left ventricle (LV) and as a percent of the risk region in control and 
CLB54-treated baboons. *p < 0.05 compared with CLB54-treated 
animals. 
administered 20 rain before reflow reduced infarct size by 50% 
from 41 _+ 20% to 19 + 17% of the area at risk (p < 0.02). 
Coronary blood flow. Coronary flow data are summarized 
in Table 1. Ten minutes and 4 h after reflow, coronary flow in 
the risk region was greater in CLB54-treated than control 
animals. 
There was no relation between transmural coronary flow 
(collateral flow) in the risk region during occlusion and infarct 
size in either group. 
The size of the no or low reflow region expressed as a 
percent of the ischemic zone was 36 _+ 28% in control and 21 _+ 
25% in CLB54-treated baboons (p = 0.10). 
Myeloperoxidase. Myeloperoxidase activity is summarized 
in Figure 3. Neutrophil accumulation was low in the nonisch- 
emic zone endocardial and epicardial ayers of both control 
and CLB54-treated animals. However, in the risk region 
transmural myeloperoxidase activity expressed as a percent of 
nonischemic zone myeloperoxidase activity was 640 _+ 420% in 
control baboons (or 1.6 _+ 1.1 U/100 mg of the left ventricle) 
and 210 _+ 60% (or 0.5 _+ 0.2 U/100 mg of the left ventricle) in 
CLB54-treated animals (p < 0.02). The reduction of endocar- 
dial myeloperoxidase activity was of borderline significance 
(p = 0.06), but that of epicardial myeloperoxidase activity was 
significant (p < 0.01). 
Reperfusion arrhythmias. Development and severity of 
reperfusion arrhythmias was not different in the two groups. 
Table 1. Coronary Blood Flow in Ischemic and Nonischemic Regions 
Nonischemic Zone Ischemic Zone 
Control Group CLB54 Group Control Group CLB54 Group 
(ml/min/lO0 g LV) (ml/min/lO0 g LV) (ml/min/lO0 g LV) (ml/min/lO0 g LV) 
Occlusion 92 : ~ 90 _+ 39 10 _+ 6 8 +- 6 
Early reflow* 154 + 55 145 _+ 74 197 _+ 160 360 -+ 209t 
Late reflow* 76 _+ 19 98 _+ 31 48 +_ 20 84 _+ 365 
*Test for significance was unpaired t test for late reflow data (normal data) and Mann-Whitney test for early reflow 
data (nonnormal data). See text for details, tp < 0.06 compared with control group (Mann-Whitney test). Sp < 0.03 
compared with control group (unpaired t test). Data presented are mean value + SD. LV = left ventricle. 
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Figure 3. Myeloperoxidase ctivity in the ischemic zone expressed asa 
percent of myeloperoxidase ctivity in the nonischcmic zone (NIZ). 
Myeloperoxidase values for endocardial (ENDO) and epicardial (EPI) 
regions and transmurally (TRANS) are shown. *p < 0.05 compared 
with CLB54-treated baboons. See text for details. 
Four baboons developed ventricular tachycardia, nd two had 
accelerated idioventricular rhythm in the CLB54-treated 
group; five animals developed ventricular tachycardia, nd one 
had ventricular fibrillation in the control group. Four animals 
in each group received one 30-mg bolus of lidocaine at the 
onset of reflow for their arrhythmia. One animal in the 
CLB54-treated group received 1 mg of atropine intravenously 
for bradycardia atonset of reflow. 
Ventricularfunction. Preocclusion ejection fraction was the 
same in both groups (51 -+ 12% and 46 _+ 11%, control and 
CLB54, respectively). Myocardial infarction was associated 
with a significant and identical decline (-17% absolute change 
in ejection fraction) in ejection fraction in the control and 
CLB54-treated baboons. Similarly, when regional function was 
assessed by median cord shortening in the five segments of the 
Figure 4. Change in chord shortening in control and CLB54-treated 
baboons. Anterior chord shortening is the average ofthe midanterior 
and anteroapical hord shortening; inferior chord shortening is the 
average of the inferobasal and midinferior wall chord shortening. See 
text for details. *p < 0.05 compared with CLB54-treated animals. 
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right anterior oblique ventriculogram, there was no difference 
between the two groups. 
However, when anterior wall function was defined as the 
average cord shortening of the midanterior and apical seg- 
ments, there was a significant difference between the groups in 
the decline in anterior wall function, the extent of decline in 
the CLB54-treated group being half that of controls (Fig. 4). 
However, there was no relation between i farct size, expressed 
as a percent of the left ventricle or risk region, and the decline 
in regional function. Function in the nonischemic nferior left 
ventricular wall was not different in the two groups. 
Discuss ion  
The present study shows that CLB54 administered within 
20 min of reflow reduces infarct size and preserves regional 
function in short-term closed-chest primate model of myocar- 
dial ischemia nd reperfusion. Reduction in infarct size was 
accompanied by a reduction i  myeloperoxidase activity in the 
ischemic region, consistent with a mechanism involving inhibi- 
tion of neutrophil sequestration. I  addition, improved imme- 
diate and late postreflow coronary blood flow suggests preser- 
vation of ischemic region microvascular integrity with CLB54 
treatment. 
Relation to previous tudies. A number of studies investi- 
gating the ability of anti-leukocyte-adhesion therapies have 
been performed in ischemia-reperfusion models, such as the 
rabbit ear (8), lung transplantation (5), hepatic ischemia nd 
reperfusion (4), and myocardial stunning (6) and infarction 
(7,9). These studies demonstrated that tissue dysfunction or 
necrosis can be minimized by inhibition of neutrophil- 
endothelial cell adhesion using one of a number of anti-CD18 
or anti-CDll (a, b or c) monoclonal ntibodies. 
Several studies have used monoclonal ntibodies directed 
against he CDll/CD18 heterodimer in an attempt to limit 
myocardial reperfusion i jury. One preliminary study (21) in 
primates reported that R15.7, an anti-CD18 antibody, admin- 
istered 30 min before coronary occlusion, reduced infarct size 
from 27% to 9% of the area at risk, improved regional function 
in the ischemic area as measured by sonomicrometry and 
reduced the incidence of ventricular fibrillation but did not 
improve the recovery of microvascular flow. That study (21) 
differs from ours in that anti-CD18 therapy was administered 
before vessel occlusion. In addition, we found an improvement 
in both early and late reperfusion coronary blood flow and no 
difference in the development of serious arrhythmias. Differ- 
ences in timing of antibody administration a d in the charac- 
teristics of the antibody, itself, may account for these disparate 
results. However, the studies are similar in their most impor- 
tant finding--that anti-CD18 therapy reduces infarct size in 
the primate. 
Two studies have been reported in dogs. Simpson et al. (9) 
showed that an anti-Mo 1 (904, anti-CDllB) antibody reduced 
infarct size by 46% in dogs treated with i mg/kg. The reduction 
in infarct size was associated with a reduction in neutrophil 
accumulation i  the risk region (9). These data are consistent 
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with data from the current study. The recent study of Tanaka 
et al. (22) showed a dissociation between eutrophil seques- 
tration and improvement in microvascular flow on the one 
hand and infarct size on the other. In particular, despite a 
marked reduction in neutrophil sequestration a d improved 
microvascular flow in anti-CD18-treated dogs, there was no 
reduction in infarct size (22). 
The reason for the discrepancy in infarct size reduction 
between these two studies is unclear. Treatment with antiad- 
hesion therapy inhibited neutrophil sequestration i both 
studies, yet infarct size was affected only in the study of 
Simpson et al. (9). This is particularly interesting because, as 
pointed out by Tanaka et al. (22), the antibody used in their 
study, 904, is directed against CDllb. Heterodimers consisting 
of CD18 associated with CDlla or CD11c would presumably 
not be inhibited. Why blocking only a single CD11 subtype 
would be effective while an anti-CD18 therapy, which should 
block all CDll/CD18 heterodimers known, would not (22) is 
unclear. 
Other methods of interfering with the effect of neutrophils 
on reperfused myocardium have also been applied. Litt et al. 
(23) removed neutrophils mechanically, using filters just before 
reflow, and demonstrated significant myocardial preservation. 
More recently, Ma et al. (24) showed that inhibition of L-selectin- 
mediated neutrophil adhesion with a monoclonal antibody 
(DREG-200) directed against his adhesion molecule reduced 
infarct size in a feline model of myocardial ischemia nd reper- 
fusion. That study demonstrated that inhibition of the early, loose 
neutrophil adherence--a first step in neutrophil sequestration 
that appears to be necessary before firm CDll/CD18-mediated 
adherence can take place--can also reduce infarct size. 
In the present study, anti-CD18 therapy with CLB54 re- 
duced infarct size in the baboon independent of collateral f ow. 
Previous tudies (25) have noted a similar absence of a relation 
between collateral flow and infarct size in primates, most likely 
because primates have consistently ow collateral flow (usually 
<10 ml/min per 100 g of left ventricle). In dogs, most studies 
have shown a close relation between collateral flow and infarct 
size (22,26), with the degree of collateral flow being more 
variable and greater than that seen in primates. 
Interpretation. The hypothesis underlying the use of 
CLB54 for inhibition of neutrophil adhesion to endothelial 
cells is that reduction of neutrophil sequestration i the 
vascular space of an organ would prevent or minimize 
reperfusion-related parenchymal damage. The reduction in 
risk region neutrophil levels in CLB54-treated animals sup- 
ports this hypothesis because neutrophil levels are propor- 
tional to tissue neutrophil density (20). The increase in early 
and late reflow in the risk region of CLB54-treated animals 
compared with controls provides evidence that inhibition of 
neutrophil adhesion by CLB54 also reduces the damage sec- 
ondary to mechanical nd biochemical effects of neutrophils on 
the microvasculature. Failure to reduce infarct size using more 
modest doses of CLB54 in preliminary studies was associated 
with an intermediate r duction in neutrophil levels and no 
preservation ofmicrovascular perfusion. 
Although these data support the primary hypothesis under- 
lying the present study, it remains possible that the association 
among reduced neutrophil accumulation, improved microvas- 
cular flow and infarct size reduction is not directly causal. 
Perhaps in addition to reducing neutrophil sequestration, 
CLB54 treatment inhibits other destructive actions of those 
neutrophils that are sequestered. Despite CLB54 treatment, 
neutrophils still do accumulate in the risk region. Adequate 
blockade of CD18 with CLB54 may prevent these sequestered 
neutrophils from promoting further tissue damage perhaps by 
inhibiting diapedesis, neutrophil attachment to myocytes or 
perhaps by inhibiting steps leading to neutrophil release of 
lysosomal enzymes or generation of free radicals. This may 
also explain part of the discrepancy among studies of CD18 
inhibition that uniformly show inhibition of neutrophil seques- 
tration but differ in infarct size reduction. 
The relation among CD18 occupancy, in vitro neutrophil 
adhesion inhibition and in vivo efficacy was evaluated in the 
present study. In vitro characterization f CLB54 showed 
half-maximal occupancy of CD18 binding sites at a level of 
0.2 tzg/ml. However, half-maximal inhibition of isolated neu- 
trophil binding to HUVECs was achieved at a 10-fold higher 
dose (2 ~g/ml); and half-maximal inhibition in whole blood 
required aconcentration f 20/zg/ml. A level of -50 tzg/ml is 
achieved when 1 mg/kg is given to the baboon. Yet at more 
than twice the concentration required for half-maximal inhibi- 
tion of neutrophil adhesion to HUVECs in whole blood, 
CL1354 failed to inhibit the reverse-phase Arthus reaction and 
failed to reduce infarct size in vivo in the baboon. Indeed, 
dosages <10 mg/kg (free antibody levels >400 tzg/ml) of 
CLB54 failed to inhibit either of these effects. These data 
demonstrate hat in vitro antibody characterization f both 
occupancy and neutrophil adhesion i hibition do not necessar- 
ily correlate with doses required for efficacy in vivo. A biolog- 
ical assay, such as the reverse passive Arthus reaction, is 
perhaps a better method of determining effective dosages. 
Conclusions. CLB54 administered at doses >10 mg/kg 
reduces infarct size in a baboon model of 90 min of ischemia 
followed by 4 h of reperfusion. Although the mechanism of 
benefit appears to be related to reduced sequestration of
neutrophils in the myocardium, other potential contributing 
mechanisms cannot be excluded. Although interference with 
the normal process of inflammation appears necessary to 
minimize reperfusion injury, deleterious effects on infarct 
healing, leading to aneurysm formation or myocardial rupture, 
and increased susceptibility to infection may result. Further 
long-term studies in animal models will be required to define 
both the duration of benefit and the potentially harmful 
consequences of such treatment. 
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